ClinicalTrials.gg
RecruitingNCT07671911OCEAN-1Updated Nov 13, 2026

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

A Phase 3 interventional study of NAL ER and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Trevi Therapeutics. Recruiting at 32 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Trevi Therapeutics · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 13, 2026Site recruiting status changed18 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Planned enrollment
35th of 188
306 · median 61
Started
2026
with 15 others
Phase 3
37 of 236
6 open now
Primary completion
2028-06
later than 33 of 50 live
Registered
232nd of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 35th largest by planned enrollment of the 188 interventional ones that give a count, is one of 16 that started in 2026, is one of 37 in phase 3, reaches primary completion later than 33 of the 50 other live ones, and was the 232nd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of IPF as determined by the Investigator based on American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) clinical practice guidelines.
  • Chronic cough for ≥8 weeks prior to Screening.
  • PGI-Severity Score ≥ 2 at Screening.
  • Forced vital capacity (FVC) ≥40 percent (%) of predicted at Screening.
  • Diffusing capacity for carbon monoxide (DLCO) ≥25% of predicted during Screening or within 12 weeks prior to Screening.
  • Participants who are currently taking antifibrotic medication (nintedanib, pirfenidone, nerandomilast) approved for IPF should be on a stable dose for at least 6 weeks prior to the Baseline Visit.

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis or clinical suspicion of an upper or lower respiratory tract infection in the last 8 weeks prior to the Screening visit or during Screening.
  • Hospitalization for any respiratory illness (including acute exacerbation of IPF) within 2 months prior to Screening.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
306 participants (estimated)

Study arms

  • Experimental
    NAL ER 54 mg

    Participants will undergo a 2-week blinded titration period (twice daily \[BID\] dosing with one NAL ER once daily \[QD\] dose and one placebo QD dose) followed by a fixed dose treatment period receiving NAL ER 54 milligrams (mg) BID for 52 weeks.

    Drug: NAL ER · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants will undergo a 2-week blinded titration period followed by a fixed dose treatment period receiving a matching placebo BID for 52 weeks.

    Drug: Placebo

Interventions

  • DrugNAL ER

    Oral tablets

    Also known as: Nalbuphine

  • DrugPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Relative Change from Baseline in 24-hour Cough Frequency at Week 26

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Absolute Change from Baseline in the Cough Severity Numerical Rating Scale (CS-NRS) at Week 26

    Time frame: Baseline, Week 26

  2. Relative Change from Baseline in 24-hour Cough Frequency at Week 6

    Time frame: Baseline, Week 6

  3. Percentage of Participants Achieving ≥50% Reduction from Baseline in 24-hour Cough Frequency at Week 26

    Time frame: Baseline, Week 26

  4. Absolute Change from Baseline in the Evaluating Respiratory Symptoms in Idiopathic Pulmonary Fibrosis (E:RS-IPF) Cough Domain at Week 26

    Time frame: Baseline, Week 26

  5. Percentage of Participants Achieving a ≥3-point Improvement from Baseline in CS-NRS at Week 26

    Time frame: Baseline, Week 26

  6. Absolute Change from Baseline in the E:RS IPF Breathlessness Domain at Week 26

    Time frame: Baseline, Week 26

  7. Relative Change from Baseline in 24-hour Cough Frequency

    Time frame: Baseline up to Week 54

  8. Absolute Change from Baseline in 24-hour Cough Frequency

    Time frame: Baseline up to Week 54

  9. Percentage of Participants Achieving ≥30%, ≥50% and ≥75% Reduction from Baseline in 24-Hour Cough Frequency

    Time frame: Baseline up to Week 54

  10. Absolute Change from Baseline in the E-RS:IPF Cough Domain

    Time frame: Baseline up to Week 54

  11. Absolute Change from Baseline in the E-RS:IPF Total Score and Domain Scores (IPF-Breathlessness, IPF-Cough, IPF-Sputum, and IPF-Chest Symptoms)

    Time frame: Baseline up to Week 54

  12. Absolute Change from Baseline in the CS-NRS

    Time frame: Baseline up to Week 54

  13. Percentage of Participants Achieving a ≥3-Point Improvement from Baseline in CS-NRS

    Time frame: Baseline up to Week 54

  14. Absolute Change from Baseline in the Leicester Cough Questionnaire (LCQ) Total Scores

    Time frame: Baseline up to Week 54

  15. Percentage of Participants Achieving a 1.3-Point Increase (Improvement) from Baseline in LCQ Total Score

    Time frame: Baseline up to Week 54

  16. Absolute Change from Baseline in Each LCQ Domain Score (Physical, Psychological, Social)

    Time frame: Baseline up to Week 54

  17. Change from Baseline in the European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) at Week 26

    Time frame: Baseline, Week 26

  18. Relative Change from Baseline in Awake Cough Frequency

    Time frame: Baseline up to Week 54

  19. Relative Change from Baseline in Sleep Cough Frequency

    Time frame: Baseline up to Week 54

  20. Absolute Change from Baseline in the Patient Global Impression of Severity (PGI-S) Cough Score

    Time frame: Baseline up to Week 54

  21. Absolute Change from Baseline in the Patient Global Impression of Change (PGI-C) Cough Score

    Time frame: Baseline up to Week 54

  22. Percentage of Participants with Improvements by ≥1 and ≥2 Categories from Baseline on the PGI-S Cough

    Time frame: Baseline up to Week 54

  23. Safety and Tolerability as Assessed by Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to Week 57

07

Study locations

31 of 32 sites recruiting
  • NewportNativeMD, Inc.
    Newport Beach, California 92663-3600, United States
    Recruiting
  • Palmtree Clinical Research
    Palm Springs, California 92262, United States
    Completed

    Not enrolling at this site — choose another above.

  • Paradigm Clinical Research Centers, Inc. - Redding
    Redding, California 96001, United States
    Recruiting
  • Critical Care Pulmonary And Sleep Associates (CCPSA) - West Clinic
    Lakewood, Colorado 80228, United States
    Recruiting
  • Meris Clinical Research
    Brandon, Florida 33511, United States
    Recruiting
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
    Recruiting
  • Clinical Research Specialists, LLC - Kissimmee
    Kissimmee, Florida 34746-4654, United States
    Recruiting
  • Pulmonary Specialists of The Palm Beaches
    Loxahatchee Groves, Florida 33470, United States
    Recruiting
  • Clinical Research and Associates, Inc.
    Miami, Florida 33126, United States
    Recruiting
  • Avanza Medical Center
    Pensacola, Florida 32503, United States
    Recruiting
  • Coastal Pulmonary & Critical Care, PLC
    St. Petersburg, Florida 33704-2733, United States
    Recruiting
  • Baycare Medical Group Primary Care and Rheumatology - Tampa
    Tampa, Florida 33614, United States
    Recruiting
  • Piedmont Atlanta Hospital (PAH)
    Atlanta, Georgia 30309, United States
    Recruiting
  • University of Kentucky - Div. of Pulmonary, Critical Care, and Sleep Medicine
    Lexington, Kentucky 40536, United States
    Recruiting
  • Tulane Clinic
    New Orleans, Louisiana 70112, United States
    Recruiting
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
  • Hannibal Regional Hospital
    Hannibal, Missouri 63401, United States
    Recruiting
  • Renown Regional Medical Center - Center for Advanced Medicine B
    Reno, Nevada 89502, United States
    Recruiting
  • Montefiore Medical Center
    The Bronx, New York 10467-2401, United States
    Recruiting
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
    Recruiting
  • Clinical Research of Gastonia (CRG)
    Gastonia, North Carolina 28054, United States
    Recruiting
  • Pulmonlx, LLC
    Greensboro, North Carolina 27403, United States
    Recruiting
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • Layrek Clinical Research
    Tulsa, Oklahoma 74133, United States
    Recruiting
  • Clinical Research Associates of Central, PA, LLC
    DuBois, Pennsylvania 15801, United States
    Recruiting
  • Jefferson Health- Thomas Jefferson University Hospital- Center City Campus
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Anmed Medical Center
    Anderson, South Carolina 29621, United States
    Recruiting
  • Horizon Clinical Research Group
    Cypress, Texas 77429, United States
    Recruiting
  • El Paso Pulmonary Association, PA
    El Paso, Texas 79902, United States
    Recruiting
  • Elevate Clinical Research
    Houston, Texas 77058, United States
    Recruiting
  • Intermountain MedicalL Center- PulmonaryY and Critical Care Research
    Murray, Utah 84107, United States
    Recruiting
  • Pulmonary Associates of Richmond Inc. (PAR) - West Broad Location
    Richmond, Virginia 23230-1710, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jun 26, 2026
StartActual
Jun 29, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jul 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
18 sites added, 5 sites removed. Palmtree Clinical Research is now Completed
Show 18 added (18 United States)
  • Renown Regional Medical Center - Center For Advanced Medicine B · Reno, United States
  • Montefiore Medical Center · The Bronx, United States
  • Intermountain MedicalL Center- PulmonaryY and Critical Care Research · Murray, United States
  • NewportNativeMD, Inc. · Newport Beach, United States
  • Critical Care Pulmonary And Sleep Associates (CCPSA) - West Clinic · Lakewood, United States
  • Mayo Clinic Jacksonville · Jacksonville, United States
  • Clinical Research Specialists, LLC - Kissimmee · Kissimmee, United States
  • Avanza Medical Center · Pensacola, United States
  • Baycare Medical Group Primary Care and Rheumatology - Tampa · Tampa, United States
  • Piedmont Atlanta Hospital (PAH) · Atlanta, United States
  • University of Kentucky - Div. of Pulmonary, Critical Care, and Sleep Medicine · Lexington, United States
  • Mayo Clinic Rochester · Rochester, United States
  • Renown Regional Medical Center - Center for Advanced Medicine B · Reno, United States
  • University of North Carolina at Chapel Hill · Chapel Hill, United States
  • Pulmonlx, LLC · Greensboro, United States
  • Layrek Clinical Research · Tulsa, United States
  • Jefferson Health- Thomas Jefferson University Hospital- Center City Campus · Philadelphia, United States
  • Pulmonary Associates of Richmond Inc. (PAR) - West Broad Location · Richmond, United States
Show 5 removed
  • Newportnativemd, Inc. · Newport Beach, United States
  • Critical Care Pulmonary and Sleep Associates (Ccpsa) - West Clinic · Lakewood, United States
  • Clinical Research Specialists, Llc - Kissimmee · Kissimmee, United States
  • Renown Regional Medical Center - Center For Advanced Medicine B · Reno, United States
  • Pulmonary Associates of Richmond Inc (Par) - West Broad Location · Richmond, United States
across 2 updates, Oct 13, 2026 – Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    15 sites added, 5 sites removed. Palmtree Clinical Research is now Completed
    Show 15 added (15 United States)
    • NewportNativeMD, Inc. · Newport Beach, United States
    • Critical Care Pulmonary And Sleep Associates (CCPSA) - West Clinic · Lakewood, United States
    • Mayo Clinic Jacksonville · Jacksonville, United States
    • Clinical Research Specialists, LLC - Kissimmee · Kissimmee, United States
    • Avanza Medical Center · Pensacola, United States
    • Baycare Medical Group Primary Care and Rheumatology - Tampa · Tampa, United States
    • Piedmont Atlanta Hospital (PAH) · Atlanta, United States
    • University of Kentucky - Div. of Pulmonary, Critical Care, and Sleep Medicine · Lexington, United States
    • Mayo Clinic Rochester · Rochester, United States
    • Renown Regional Medical Center - Center for Advanced Medicine B · Reno, United States
    • University of North Carolina at Chapel Hill · Chapel Hill, United States
    • Pulmonlx, LLC · Greensboro, United States
    • Layrek Clinical Research · Tulsa, United States
    • Jefferson Health- Thomas Jefferson University Hospital- Center City Campus · Philadelphia, United States
    • Pulmonary Associates of Richmond Inc. (PAR) - West Broad Location · Richmond, United States
    Show 5 removed
    • Newportnativemd, Inc. · Newport Beach, United States
    • Critical Care Pulmonary and Sleep Associates (Ccpsa) - West Clinic · Lakewood, United States
    • Clinical Research Specialists, Llc - Kissimmee · Kissimmee, United States
    • Renown Regional Medical Center - Center For Advanced Medicine B · Reno, United States
    • Pulmonary Associates of Richmond Inc (Par) - West Broad Location · Richmond, United States
    + 1 other change: verification date
  2. Oct 13, 2026
    3 sites added
    Show 3 added (3 United States)
    • Renown Regional Medical Center - Center For Advanced Medicine B · Reno, United States
    • Montefiore Medical Center · The Bronx, United States
    • Intermountain MedicalL Center- PulmonaryY and Critical Care Research · Murray, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07671911
Lead sponsor
Trevi Therapeutics
Responsible party
Sponsor
First posted
Jun 26, 2026
Start date
Jun 29, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Paula Buckley
Contact
Paula.Buckley@trevitherapeutics.com
(203) 304-2499
Chief Development Officer
study director · Trevi Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalbuphine

Start the discussion